Gilead Sciences, Inc. $GILD Shares Purchased by ING Groep NV

ING Groep NV lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 95.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 364,354 shares of the biopharmaceutical company’s stock after acquiring an additional 177,642 shares during the quarter. ING Groep NV’s holdings in Gilead Sciences were worth $44,721,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Paulson Wealth Management Inc. boosted its holdings in Gilead Sciences by 1.8% during the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after buying an additional 67 shares in the last quarter. Essex Financial Services Inc. raised its position in Gilead Sciences by 0.9% during the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after acquiring an additional 71 shares during the period. Alpha Cubed Investments LLC grew its holdings in shares of Gilead Sciences by 1.1% during the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after buying an additional 75 shares in the last quarter. Personal CFO Solutions LLC grew its holdings in shares of Gilead Sciences by 1.7% during the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 76 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 1.7% during the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after buying an additional 76 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Citi and Scotiabank both reiterated bullish views on Gilead, with each firm maintaining a Buy rating, which can support investor confidence in the stock. Gilead Sciences (GILD) Receives a Buy from Citi
• Positive Sentiment: Gilead highlighted progress on lenacapavir in South Africa, where the government and Global Fund are accelerating access to the HIV prevention drug, reinforcing the company’s growth story in HIV. Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
• Positive Sentiment: Gilead and Lakefront completed the acquisition of Ouro Medicines, expanding the inflammation/autoimmune pipeline around gamgertamig, a potential first-in-class T cell engager. Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
• Positive Sentiment: Gilead’s inclusion in a list of “best quality growth stocks” may add to the market’s view that the company remains a high-quality large-cap healthcare name. 5 Best Quality Growth Stocks to Buy
• Neutral Sentiment: Industry-wide biopharma M&A remains active, and Gilead was mentioned among the sector’s deal-making leaders, which keeps takeover speculation and pipeline deal optionality in focus. Gilead, Merck, Eli Lilly Lead $106 Billion Biopharma Takeover Wave In 2026
• Neutral Sentiment: Gilead also reported a clinical milestone in its IDEAL PBC trial, which could become a future catalyst if the study continues to progress positively. Gilead’s IDEAL PBC Trial Reaches Key Milestone, Setting Up a New Liver Disease Catalyst

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the transaction, the chief financial officer directly owned 173,191 shares in the company, valued at approximately $22,907,973.57. This trade represents a 1.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the transaction, the insider owned 125,779 shares in the company, valued at $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 68,000 shares of company stock valued at $9,047,570 over the last quarter. Company insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of several recent research reports. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a research report on Wednesday, May 20th. Argus upped their price target on Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Weiss Ratings cut Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. Royal Bank Of Canada reiterated an “overweight” rating and set a $122.00 price target on shares of Gilead Sciences in a research note on Monday, June 1st. Finally, Needham & Company LLC reissued a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a research report on Monday, February 23rd. Twenty-six investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $156.93.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $129.16 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. Gilead Sciences, Inc. has a fifty-two week low of $104.46 and a fifty-two week high of $157.29. The firm has a market capitalization of $160.36 billion, a PE ratio of 17.60 and a beta of 0.31. The stock’s 50-day simple moving average is $134.38 and its 200-day simple moving average is $134.31.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s payout ratio is 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.